Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy.
Pantuck
Allan J
AJ
Zomorodian
Nazy
N
Belldegrun
Arie S
AS